Embrex, a developer of in-egg services for the poultry industry, posted a $200,000 loss for the fourth quarter.

A $2.3 million write down for the acquisition of a gener sort system put Embrex in the red. Its revenues were unchanged for the quarter compared to 2002 when the company posted net income of $1.4 million.

For the year, Embrex had revenues of $46 million, up 2 percent over 2002, and net income of $7.6 million, a 6 percent increase. But among its revenue was a $5 million litigation settlement from Fort Dodge Animal Health, the company said.

During 2003, Embrex won USDA approval for a vaccine to fight
Newcastle disease, won four patents, and completed construction of a manufacturing facility for its Inovocox vaccine.

Embrex: www.Embrex.com